Aroa Biosurgery, (AROA) is delighted to announce the appointment of award-winning medical researcher and inventor, Dr. Catherine Mohr as a…
Highlights A retrospective analysis of real-world data published in the ‘International Wound Journal’ compared the wound closure times for diabetic…
Read MoreHighlights• AROA’s Myriad Matrix™ is further validated in a clinical study and peer-reviewed publication in Journal of Wound Care.• Study…
Read MoreHIGHLIGHTS US medical procedure numbers continue to reflect a positive trend supporting improved sales momentum. AROA maintains its published product…
Read MoreAroa Biosurgery is pleased to release its first Annual Report since successfully completing its IPO and Admission onto the ASX…
Read MoreHIGHLIGHTS H2 FY21 product revenues (unaudited) grew 16% on H2FY20 to $13.8m on a constant currency basis (i.e. eliminating impact…
Read MoreHIGHLIGHTS U.S. FDA 510(k) clearance received for a new Aroa Biosurgery product named Myriad Morcells™, a morcellized (powder) format of…
Read MoreHIGHLIGHTS Aroa’s Myriad™ may be used successfully under a tissue flap to reduce surgical complications in the flap reconstruction of…
Read MoreHIGHLIGHTS Aroa to expand on its own direct field sales presence in the United States market in a move expected…
Read MoreHIGHLIGHTS Aroa’s Myriad™ is further validated in a clinical study and peer-reviewed publication – Journal of Wound Care.Study shows 100%…
Read More